Does the media favor AGL or IDHC?

In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANGLE 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integrated Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IDHC or PRM?

In the previous week, Proteome Sciences had 2 more articles in the media than Integrated Diagnostics. MarketBeat recorded 3 mentions for Proteome Sciences and 1 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integrated Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Proteome Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MXCT or IDHC?

In the previous week, MaxCyte and MaxCyte both had 1 articles in the media. MaxCyte's average media sentiment score of 0.23 beat Integrated Diagnostics' score of 0.00 indicating that MaxCyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integrated Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Integrated Diagnostics (IDHC) Competitors

GBX 0.53 -0.02 (-3.28%)

As of 04:55 AM Eastern

Compare

IDHC vs. AGL, GENI, PRM, VRCI, and MXCT

Should you buy Integrated Diagnostics stock or one of its competitors? Integrated Diagnostics's main competitors and comparable companies include ANGLE (AGL), GENinCode (GENI), Proteome Sciences (PRM), Verici Dx (VRCI), and MaxCyte (MXCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Integrated Diagnostics compare to ANGLE?

ANGLE (LON:AGL) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

17.5% of ANGLE shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 2.7% of ANGLE shares are held by company insiders. Comparatively, 78.4% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ANGLE has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, meaning that its share price is 57% less volatile than the broader market.

Integrated Diagnostics has a net margin of 16.49% compared to ANGLE's net margin of -1,444.04%. Integrated Diagnostics' return on equity of 39.61% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANGLE	-1,444.04%	-191.36%	-29.89%
Integrated Diagnostics	16.49%	39.61%	9.69%

In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANGLE	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integrated Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Integrated Diagnostics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A
Integrated Diagnostics	£9.17B	0.00	£4.01T	£250.03	0.00

Summary

Integrated Diagnostics beats ANGLE on 9 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to GENinCode?

GENinCode (LON:GENI) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Integrated Diagnostics had 1 more articles in the media than GENinCode. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for GENinCode. GENinCode's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company	Overall Sentiment
GENinCode	Neutral
Integrated Diagnostics	Neutral

Integrated Diagnostics has a net margin of 16.49% compared to GENinCode's net margin of -185.47%. Integrated Diagnostics' return on equity of 39.61% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-185.47%	-409.40%	-63.99%
Integrated Diagnostics	16.49%	39.61%	9.69%

Integrated Diagnostics has higher revenue and earnings than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£3.08M	2.08	-£6.10M	-£2.08	N/A
Integrated Diagnostics	£9.17B	0.00	£4.01T	£250.03	0.00

GENinCode has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, meaning that its stock price is 57% less volatile than the broader market.

11.4% of GENinCode shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 8.4% of GENinCode shares are owned by insiders. Comparatively, 78.4% of Integrated Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Integrated Diagnostics beats GENinCode on 9 of the 12 factors compared between the two stocks.

How does Integrated Diagnostics compare to Proteome Sciences?

Integrated Diagnostics (LON:IDHC) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Integrated Diagnostics has higher revenue and earnings than Proteome Sciences. Proteome Sciences is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated Diagnostics	£9.17B	0.00	£4.01T	£250.03	0.00
Proteome Sciences	£3.76M	1.28	-£4.08M	-£1.04	N/A

In the previous week, Proteome Sciences had 2 more articles in the media than Integrated Diagnostics. MarketBeat recorded 3 mentions for Proteome Sciences and 1 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integrated Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Proteome Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Integrated Diagnostics has a net margin of 16.49% compared to Proteome Sciences' net margin of -81.50%. Integrated Diagnostics' return on equity of 39.61% beat Proteome Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integrated Diagnostics	16.49%	39.61%	9.69%
Proteome Sciences	-81.50%	33.80%	-19.25%

Integrated Diagnostics has a beta of 0.432, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, suggesting that its stock price is 84% less volatile than the broader market.

7.7% of Integrated Diagnostics shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 78.4% of Integrated Diagnostics shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Integrated Diagnostics beats Proteome Sciences on 10 of the 12 factors compared between the two stocks.

How does Integrated Diagnostics compare to Verici Dx?

Verici Dx (LON:VRCI) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Integrated Diagnostics had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for Verici Dx. Integrated Diagnostics' average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that Integrated Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Verici Dx	Negative
Integrated Diagnostics	Neutral

Integrated Diagnostics has a net margin of 16.49% compared to Verici Dx's net margin of -193.05%. Integrated Diagnostics' return on equity of 39.61% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-193.05%	-138.93%	-26.14%
Integrated Diagnostics	16.49%	39.61%	9.69%

Verici Dx has a beta of 1.222, meaning that its share price is 22% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, meaning that its share price is 57% less volatile than the broader market.

15.9% of Verici Dx shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 1.2% of Verici Dx shares are owned by insiders. Comparatively, 78.4% of Integrated Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Integrated Diagnostics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£3.66M	1.25	-£6.56M	-£0.90	N/A
Integrated Diagnostics	£9.17B	0.00	£4.01T	£250.03	0.00

Summary

Integrated Diagnostics beats Verici Dx on 10 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to MaxCyte?

MaxCyte (LON:MXCT) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

24.0% of MaxCyte shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 1.9% of MaxCyte shares are owned by company insiders. Comparatively, 78.4% of Integrated Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, indicating that its stock price is 57% less volatile than the broader market.

In the previous week, MaxCyte and MaxCyte both had 1 articles in the media. MaxCyte's average media sentiment score of 0.23 beat Integrated Diagnostics' score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integrated Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Integrated Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	£32.29M	0.04	-£45.08M	-£40.00	N/A
Integrated Diagnostics	£9.17B	0.00	£4.01T	£250.03	0.00

Integrated Diagnostics has a net margin of 16.49% compared to MaxCyte's net margin of -119.69%. Integrated Diagnostics' return on equity of 39.61% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-119.69%	-11.59%	-11.07%
Integrated Diagnostics	16.49%	39.61%	9.69%

Summary

Integrated Diagnostics beats MaxCyte on 8 of the 12 factors compared between the two stocks.

Get Integrated Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDHC vs. The Competition

Export

Metric	Integrated Diagnostics	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£3.08M	£9.85B	£7.21B	£2.88B
Dividend Yield	1.62%	1.47%	2.57%	6.26%
P/E Ratio	0.00	68.77	272.90	366.53
Price / Sales	0.00	107.65	708.39	90,145.12
Price / Cash	N/A	26.23	77.71	27.89
Price / Book	0.00	5.43	10.46	6.43
Net Income	£4.01T	£56.67B	£3.49B	£5.89B
7 Day Performance	-1.85%	1.06%	-0.76%	-0.30%
1 Month Performance	1.92%	1.04%	-0.39%	-0.59%
1 Year Performance	-11.67%	25.47%	18.93%	20.21%

Integrated Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDHC Integrated Diagnostics	N/A	GBX 0.53 -3.3%	N/A	-8.7%	£3.08M	£9.17B	0.00	6,692
AGL ANGLE	N/A	GBX 2.35 -11.3%	N/A	-25.4%	£7.58M	£2.62M	N/A	650	News Coverage Gap Up
GENI GENinCode	N/A	GBX 0.93 -2.1%	N/A	-42.1%	£7.00M	£3.08M	N/A	2,300	Gap Down
PRM Proteome Sciences	N/A	GBX 1.59 +13.6%	N/A	-60.6%	£5.58M	£3.76M	N/A	240	News Coverage Earnings Report Gap Down
VRCI Verici Dx	N/A	GBX 0.21 -7.6%	N/A	-62.8%	£4.76M	£3.66M	N/A	19	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IDHC) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integrated Diagnostics (IDHC) Competitors

IDHC vs. AGL, GENI, PRM, VRCI, and MXCT

How does Integrated Diagnostics compare to ANGLE?

Summary

How does Integrated Diagnostics compare to GENinCode?

Summary

How does Integrated Diagnostics compare to Proteome Sciences?

Summary

How does Integrated Diagnostics compare to Verici Dx?

Summary

How does Integrated Diagnostics compare to MaxCyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDHC vs. The Competition

Integrated Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Integrated Diagnostics (IDHC) Competitors

IDHC vs. AGL, GENI, PRM, VRCI, and MXCT

How does Integrated Diagnostics compare to ANGLE?

Do institutionals & insiders believe in AGL or IDHC?

Which has more risk & volatility, AGL or IDHC?

Is AGL or IDHC more profitable?

Does the media favor AGL or IDHC?

Which has higher earnings & valuation, AGL or IDHC?

Summary

How does Integrated Diagnostics compare to GENinCode?

Does the media refer more to GENI or IDHC?

Is GENI or IDHC more profitable?

Which has stronger earnings & valuation, GENI or IDHC?

Which has more risk & volatility, GENI or IDHC?

Do insiders and institutionals believe in GENI or IDHC?

Summary

How does Integrated Diagnostics compare to Proteome Sciences?

Which has higher valuation & earnings, IDHC or PRM?

Does the media favor IDHC or PRM?

Is IDHC or PRM more profitable?

Which has more volatility & risk, IDHC or PRM?

Do insiders and institutionals believe in IDHC or PRM?

Summary

How does Integrated Diagnostics compare to Verici Dx?

Does the media prefer VRCI or IDHC?

Is VRCI or IDHC more profitable?

Which has more risk and volatility, VRCI or IDHC?

Do insiders and institutionals believe in VRCI or IDHC?

Which has stronger earnings and valuation, VRCI or IDHC?

Summary

How does Integrated Diagnostics compare to MaxCyte?

Do insiders & institutionals have more ownership in MXCT or IDHC?

Which has more volatility & risk, MXCT or IDHC?

Does the media refer more to MXCT or IDHC?

Which has better earnings & valuation, MXCT or IDHC?

Is MXCT or IDHC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDHC vs. The Competition

Integrated Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools